Project Grant R01AI189900
Award Date 9/18/25
Completion Date 8/31/30
Dollars Obligated $809K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $423,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Texas A&M University System Health Science Center. The grant, awarded on July 17, 2025, aims to develop an intein-based QF2 system for controllable protein expression in the nervous system of the Aedes aegypti mosquito. This research seeks to leverage genetic and synthetic biology tools to disrupt the propagation of...
- The Project Grant award of $449,625.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program aims to develop a novel mouse model of arthropod-borne virus (ABV) transmission. The model will co-engraft a functional human immune system and human skin organoids to better understand the human cutaneous responses to ABV transmission, which is critical for developing effective antiviral countermeasures. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $781,718 Project Grant through its Allergy and Infectious Diseases Research program (CFDA 93.855) to Loyola University of Chicago to develop a novel T cell-based vaccine to prevent Dengue and Zika virus infections. The 5-year project aims to create a vaccine that induces cytotoxic T cells targeting the Zika virus non-structural protein 3, without causing antibody-dependent enhancement observed with vaccines targeting the...
- This federal Project Grant award of $649,530.00, awarded on July 7, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of B cell receptor (BCR)-dependent infection as a mechanism of immune-mediated enhancement of Dengue virus (DENV) infection and pathogenesis. The funded research aims to explore how cross-reactive non-neutralizing antibodies, when expressed...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, has awarded a $720,588 Project Grant to the Regents of the University of Minnesota. The grant supports the "Development of Broadly Protective Vaccines Against New World Arenaviruses" project, which aims to leverage the Pichinde virus vaccine vector to develop safe and effective vaccines against pathogenic New World arenaviruses, such as the...
- This $254,250 Project Grant was awarded on July 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to understand how Chikungunya virus (CHIKV), a mosquito-borne human pathogen, infects microvascular endothelial cells, which play critical roles in vascular homeostasis and protecting against pathogens. The research aims to identify viral and host factors that restrict...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $530,385.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to conduct research on how host cell factors regulate the activity of the essential flaviviral enzyme NS3 in viral pathogens like dengue, Zika, and West Nile viruses. The research aims to define in detail how...
- This federal Project Grant award of $294,583, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel cost-effective multispecific antibody therapeutic product for dengue by Mapp Biopharmaceutical, Inc. The goal is to create a therapeutic that combines the efficacy of two broadly neutralizing antibodies into a single half-life extended molecule, enabling higher...
- This $401,185 Project Grant was awarded on July 18, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The funding will support research at the University of Nevada, Reno to study the mechanism of action of the broadly-active antiviral mosquito protein ABRAVO. The project aims to generate new tools, determine key protein residues, and analyze RNA and protein interactions to better...
- This $536,871 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to identify small molecule inhibitors against critical components of arenaviruses, which cause severe hemorrhagic fevers. The proposed studies aim to use machine learning and molecular screening to identify pan-reactive inhibitors targeting the arenavirus surface glycoprotein and RNA polymerase...